Intellia Therapeutics, Inc.
NTLA
$12.35
$0.151.23%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 24.97% | 20.49% | 14.64% | 5.62% | -8.32% |
| Total Depreciation and Amortization | 52.15% | 54.82% | 22.47% | 2.83% | 8.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -56.35% | -48.78% | -33.37% | -13.34% | 34.29% |
| Change in Net Operating Assets | -203.47% | -720.91% | -657.66% | -524.05% | 62.06% |
| Cash from Operations | 3.71% | -13.14% | -15.11% | -12.14% | 6.97% |
| Capital Expenditure | 88.20% | 80.46% | 68.59% | 65.49% | 68.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -8.03% | 74.47% | 1,248.34% | 198.94% | 99.16% |
| Cash from Investing | -6.53% | 81.60% | 1,665.52% | 222.07% | 121.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 31.25% | -29.21% | -54.53% | -56.28% | -33.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 31.25% | -29.21% | -54.53% | -56.28% | -33.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 105.12% | 6.25% | 256.22% | 165.31% | 68.97% |